HRCM
BIO icon

Hawk Ridge Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Hawk Ridge Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-214,376
Closed -$76.8M – 42
2023
Q3 		$76.8M Buy
214,376
+100
+0% +$38.6K 3.78% 11
2023
Q2 		$81.2M Buy
214,276
+66,500
+45% +$27.1M 4.31% 8
2023
Q1 		$70.8M Buy
147,776
+42,990
+41% +$20.1M 4.02% 10
2022
Q4 		$44.1M Buy
104,786
+6,100
+6% +$2.46M 2.98% 15
2022
Q3 		$41.2M Buy
+98,686
New +$49.2M 2.59% 18

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Hawk Ridge Capital Management's BIO Position: Q4 2023 in Review

Hawk Ridge Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 214,376 shares — an estimated $76.8M sold.

Hawk Ridge Capital Management first reported a position in BIO in Q3 2022 and held it in 5 quarters. The position peaked at $81.2M in Q2 2023. 483 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

  • Hawk Ridge Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
  • Hawk Ridge Capital Management sold 214,376 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $76.8M.
  • Hawk Ridge Capital Management first reported a position in Bio-Rad Laboratories Class A in Q3 2022 and held it in 5 quarters.
  • Hawk Ridge Capital Management's Bio-Rad Laboratories Class A position peaked at $81.2M in Q2 2023.
  • 483 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Hawk Ridge Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.